Introduction
Dramatic improvements in survival following institution of highly active antiretroviral therapy (HAART) have given rise to increased occurrence of endocrinopathies in HIV infected patients in the last two decades, which are associated with significant morbidity. Thyroid dysfunction is among the commonest endocrinopathies in HIV. Undiagnosed thyroid dysfunction, even subclinical hypothyroidism, is associated with significant morbidity and poor quality of life [1] [2] [3] [4] . Subtle thyroid dysfunction is common, believed to occur in as many as 35% of all HIV infected individuals [5] [6] [7] . In contrast overt thyroid dysfunction is less common, believed to involve 1-2% of all patients [6, 7] . Prevalence of overt primary hypothyroidism in the general population and HIV infected individuals from different studies across the globe has been reported to be 0.3% and 0-2.6%, respectively [6] [7] [8] [9] . Similarly the prevalence of subclinical hypothyroidism
Methods
Antiretroviral therapy (ART) clinic at our institute has been functional since 2004, established by the National AIDS Control Organization (NACO), India, and the World Health Organization (WHO). The clinic provides for all the necessary investigations, medications (including highly active antiretroviral therapy [HAART]), counseling, and education to all patients with HIV infection. Consecutive ambulatory patients, 18-70 years of age, with serologically documented HIV infection, in stable clinical condition without any acute, severe illness, attending the ART clinic of our hospital were considered. Severely ill patients with multiple comorbid states, which would warrant hospital admission, were excluded. Patients with vitamin-D and/or calcium supplementation in the last 6 months were excluded. Patient records were reviewed and patients having clinical data of at least 1 year of follow-up were further evaluated. Patients whose CD4 cell count records at diagnosis and at least one followup (6-12 months after diagnosis) available were included in the study. The study protocol was explained to the considered patients and only those who gave informed written consent were included. The institutional ethics committee approved the study protocol. The period of the study was from August 2014 till September 2015.
Data were collected from the patients and their records regarding the duration of diagnosis of HIV infection and details of HAART. Data was also collected regarding past or current evidence of infections including opportunistic infections (bacterial, viral, and fungal). History of clinical features suggestive of hypothyroidism or hyperthyroidism was taken. All patients underwent detailed clinical assessment, including anthropometry. The patients were called the subsequent day in fasting state for blood sampling. Blood samples of 5 mL each were collected in plain and EDTA Vacutainer (Becton Dickinson). Serum was separated from blood collected in plain Vacutainer and processed immediately for routine biochemical analysis and one aliquot of serum was stored at −20 degrees' Celsius for specific immunological (hormonal) assays. EDTA sample was processed for hematological analysis.
Chemiluminescent microparticle immunoassay (VIT-ROS ECiQ Immunodiagnostic System, Johnson & Johnson, USA) was used for estimation of free tri-iodothyronine (fT3), free tetraiodothyronine (fT4), thyroid stimulation hormone (TSH), and 25-hydroxy-vitamin-D. FT3 assay had analytical sensitivity of 0.50 pg/mL, analytical range of 0.50-22.8 pg/mL, and intra-and interassay coefficient of variation (CV) of 2.2% and 6.3%, respectively. FT4 assay had analytical sensitivity of 0.07 ng/dL and analytical range of 0.07-6.99 ng/dL with intra-and interassay coefficient of variation (CV) of 2.4% and 5.8%, respectively. TSH assay had analytical sensitivity of 0.015 mIU/L and analytical range of 0.015-100 mIU/L with intra-and interassay coefficient of variation (CV) of 3.3% and 7.2%, respectively. Serum 25-hydroxyvitamin-D (25OHD) assay had analytical sensitivity of 8.0 ng/mL, analytical range of 8-150 ng/mL, and intra-and interassay coefficient of variation (CV) of 3.4% and 5.5%, respectively. Antithyroid peroxidase antibody (anti-TPO) levels were measured by solid phase immunosorbent assay (AutoSTAT II anti-TPO, HYCOR Biomedical) and had analytical sensitivity of 1.81 U/mL and analytical range of 35-1500 U/mL with intra-and interassay coefficient of variation (CV) of 3.7% and 7.5%, respectively. CD4 cell count was performed using flow cytometry (Becton Dickinson Immunocytochemistry Systems, San Jose, CA). Serum calcium, phosphate, alkaline phosphate, and renal function tests were done using clinical chemistry autoanalyzer based on dry chemistry microslide technology (VITROS 350 chemistry system, Johnson & Johnson, USA).
The reference range of fT3, fT4, and TSH in our laboratory is 2-4.4 pg/mL, 0.6-2.2 ng/dL, and 0.5-5 mIU/L, respectively. Anti-TPO antibody titer <50 IU/mL is considered to be negative or normal. In accordance with previous literature, primary overt hypothyroidism was defined as patients having elevated TSH along with low fT4 [5, 6] . Subclinical hypothyroidism was defined as patients having elevated TSH along with normal thyroid hormone levels. Subclinical hyperthyroidism was defined as patients having suppressed TSH levels with normal thyroid hormone levels [5, 6] . Overt hyperthyroidism was defined as patients having suppressed TSH levels along with elevated fT4 and/or fT3. Sick euthyroid syndrome, a physiological adaptive phenomenon to conserve energy during periods of extreme stress and infection, was defined as patients having isolated low fT3 or low fT4 with low fT3 levels, along with low or normal TSH levels [10] . Euthyroidism was defined as clinically asymptomatic patients having normal fT3, fT4, and TSH levels. It has been reported that 1.3-6.8% HIV infected patients have isolated low TSH with normal thyroid hormone levels [11] . Hence, patients with normal fT3 and fT4 with low TSH were grouped separately. A few studies have also noted isolated low fT4 (up to 6.8% patients), a pattern distinct from sick euthyroid syndrome in patients with HIV infection, which is believed to be due to an alternation in hypothalamic-pituitary-thyroid axis [6] . Hence these patients were also grouped separately in our study. Serum 25-hydroxy-vitamin-D (25OHD) levels ≥30 ng/mL were defined as vitamin-D sufficiency, 20-30 ng/mL as vitamin-D insufficiency, and <20 ng/mL as vitamin-D deficiency [12] .
Immune reconstitution inflammatory syndrome (IRIS) in HIV infected patients is characterized by clinical deterioration in a patient secondary reestablishment of immunity following initiation of HAART [13] . It is usually observed in patients with low baseline CD4 count, which increases rapidly following initiation of HAART. HAART has been linked to increased occurrence of autoimmunity and autoimmune disorders [13, 14] . IRIS has been defined as an increased CD4 count above 200 cells/mm 3 in patients who previously had CD4 counts lower than 100-200 cells/mm 3 [15, 16] . Hence patients in our study with baseline CD4 counts less than 200 cells/mm 3 , which increased to >200 cells/mm 3 at the first follow-up following initiation of HAART, were defined to have IRIS. Parameters like age, duration of HIV infection, occurrence of opportunistic infections, baseline and posttreatment CD4 counts, IRIS, antiretroviral drugs used, vitamin-D status, and autoimmunity (anti-TPO antibody) were evaluated for their role in predicting the occurrence of thyroid dysfunction.
Subtle thyroid dysfunction is common in HIV infected individuals, believed to involve as many as 35% of all individuals [5] [6] [7] . Hence for keeping a power of 80% and type-I error at 5%, it has been calculated that we need to recruit at least 246 patients in our study for accurate assessment of thyroid dysfunction.
Statistical Analysis
Normality of the distribution of variables was assessed using the Kolmogorov-Smirnov test. Independent -test and Wilcoxon rank sum test were done for normally distributed and skewed variables, respectively. Chi-square tests were used for categorical variables. Pearson's or Spearman's correlation coefficient was calculated for normally distributed and skewed variables, respectively. Multiple linear regression analyses were done to determine variables that independently influenced the occurrence of thyroid dysfunction after adjusting for factors in different models. A value <0.05 was considered statistically significant. SPSS version 20 was used for analyses.
Results
Five hundred and twenty-seven consecutive patients with HIV infection were screened at the ART clinic, of which 370 patients who fulfilled all criteria were considered for inclusion into the study. Reasons for exclusion from the study included severe associated illness ( = 23), multiple comorbid states like chronic liver disease, chronic kidney disease ( = 11), previous steroid use ( = 25), and history of calcium or vitamin-D supplementation in last 6 months ( = 41). Fortysix patients were excluded because of less than 1-year followup and 11 were excluded due to incomplete records. Of the 370 considered patients, 11 Subclinical hypothyroidism was the most common thyroid dysfunction observed in 53 (14.76%) patients. Sick euthyroid syndrome, isolated low TSH, and isolated low T4 were observed in 16 (4.45%), 11 (3.06%), and 3 (0.84%) patients, respectively. Overt hypothyroidism and hyperthyroidism were observed in 5 (1.39%) and 2 (0.01%) patients, respectively. Anti-TPO antibody titers were positive in 3.90% (14/359) patients ( Table 1) . Occurrence of thyroid dysfunction, especially sick euthyroid syndrome, was significantly more common in females than males (Table 1 ). Males were significantly older ( = 0.001) and had significantly lower BMI ( = 0.016), baseline CD4 count ( = 0.001), and current CD4 count ( = 0.001) along with significantly higher history of IRIS ( = 0.008) ( Table 1) .
Patients with history of IRIS were older ( = 0.049), were more likely to be males ( = 0.007), had lower BMI ( = 0.002), higher history of tuberculosis ( = 0.002), and higher use of protease inhibitors ( < 0.001), and had significantly lower baseline ( < 0.001) and current CD4 cell counts ( = 0.005) ( Table 2 ). Serum fT3 was significantly higher in patients with history of IRIS ( = 0.036) ( Table 2) . The occurrence of different types of thyroid dysfunction was comparable in patients with history of IRIS as compared to those without (Table 2 ).
An inverse correlation was observed between baseline CD4 count ( = 0.031) and anti-TPO antibody titers, which persisted even after adjusting for age and body mass index ( = 0.032) ( Table 3) . Similarly an inverse correlation was observed in CD4 count at present with TSH levels, both at baseline ( = 0.043) and after adjusting for age and body mass index ( = 0.049) ( Table 3 ). Stepwise linear regression analysis revealed that anti-TPO antibody titers and CD4 cell count at the time of initial diagnosis of HIV infection were the 2 best predictors of occurrence of subclinical hypothyroidism, at baseline (Model-1), after adjusting for age and duration of HIV infection (Model-2), and after adjusting for variables in Model-2 plus weight and history of opportunistic fungal and viral infections (Model-3) ( Table 4 ). Increased anti-TPO antibody titers and lower baseline CD4 count were independent predictors of increased occurrence of subclinical hypothyroidism. Previous history of tuberculosis tended to be a good predictor of subclinical hypothyroidism later in life both at baseline ( = 0.084) and after adjusting for variables in Model-2 ( = 0.087) and Model-3 ( = 0.065) ( Table 4 ).
Discussion
The occurrence of sick euthyroid syndrome among HIV infected patients is highly variable ranging from 1.3% to 11.6% in different studies [11, [16] [17] [18] [19] . Stable, ambulatory, asymptomatic patients, with a large majority being on HAART (88.86%) with stable immune function (as evidenced by only 9.75% patients having CD4 count <200 cell/mm 3 at the time of recruitment into this study and hormonal assessment) may explain the low occurrence of sick euthyroid syndrome in our study cohort. Heterogeneity in the disease profile of the patients evaluated in different studies (duration of infection, severity of immunodeficiency, in-patient versus out-patient, associated comorbidities, and functional status) may explain this variation. A pilot study from central India reported a high prevalence of subclinical (30%) and overt hypothyroidism (10.66%) in a cohort of 150 HAART naïve newly diagnosed HIV infected patients [17] . Subclinical hypothyroidism was the commonest type of thyroid dysfunction observed in our study cohort documented in 14.76% patients. The prevalence is comparable to previous reports from other countries [6] [7] [8] [9] . However this is in contrast to a previous report from our institute where a very high occurrence of subclinical hypothyroidism (53%) was documented in patients newly diagnosed with HIV infection [20] . It is important to highlight that the patients evaluated in that study were newly diagnosed with HIV infection, had advanced immunodeficiency (mean CD4 count: 147.1 ± 84 cell/mm 3 , 70.1% had CD4 count <200 cell/mm 3 ), and were HAART naïve [20] . This is consistent with data reported from pre-HAART era and from patients newly diagnosed with HIV infection not on HAART, where the occurrence of thyroid dysfunction has been reported to be higher ranging from 10 to 40% [17, 21] . This is in contrast to our patients having mean disease duration of 5 years, with a large majority being on HAART (88.6%), being clinically stable, asymptomatic, and ambulatory with good immune function (90.25% having CD4 count >200 cell/mm 3 ; 31.75% having CD4 count >500 cell/mm 3 ).
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Journal of Thyroid Research Anti-TPO antibody titers, baseline CD4 counts, and history of tuberculosis were the best predictors of subclinical hypothyroidism in HIV infected patients in our study. Anti-TPO antibody positivity has previously been documented to be predictors of subclinical and overt hypothyroidism in normal and postpartum individuals [22, 23] . However it needs to be emphasized that, in spite of being a good predictor of subclinical hypothyroidism in our study, the prevalence of elevated anti-TPO antibody titers in our cohort was only 3.9%, which is lower than that observed in the general population (3-15%) [24] . A previous study of 642 normal individuals from northern India revealed the prevalence of anti-TPO positivity to be 21% [25] .
The inverse relation observed between current CD4 count and TSH even after adjusting for variables highlights the possible link between increased immunodeficiency and elevated TSH. Further, in the setting of low prevalence of elevated anti-TPO antibody titers, low baseline CD4 count being a strong independent predictor of subclinical hypothyroidism highlights the importance of early immunodeficiency and HIV infection per se having an important role in the genesis of subclinical hypothyroidism later in life. It is likely that patients with lower CD4 counts had higher viral load. However, HIV viral load was not evaluated in our study and is a limitation of this report. Previous history of tuberculosis being an important independent predictor of hypothyroidism in our study also highlights the importance of immunodeficiency in the pathogenesis of thyroid dysfunction (as tuberculosis is more common in the immunodeficient state). A high rate of hypothyroidism (54%) was reported from 69 HIV infected patients with multidrug resistant (MDR) tuberculosis from Mumbai, India [26] . Use of rifampicin, para-aminosalicylate (PAS), and ethionamide for treating tuberculosis has been linked to the increased occurrence of hypothyroidism in these patients [26] .
The inverse relationship observed between baseline CD4 count and anti-TPO antibody titers raises the possibility of increased immunodeficiency early in the course of disease being linked to increased occurrence of autoimmunity later. Increased autoantibody expression has previously been documented in patients of HIV infection with lower CD4+ cell counts, believed to be the result of a direct effect of the virus on endothelium, hematopoietic cells, and different tissues leading to enhancement of the cytotoxic activity of immune cells and autoantigen expression [27, 28] . Induction of immune restoration by HAART has been linked to thyroid dysfunction in some studies [29, 30] . This was primarily observed with regard to occurrence of hyperthyroidism and Graves' disease [17, 29, 30] . Graves' disease has most commonly been reported 12-36 months after HAART initiation [17] . Subclinical hyperthyroidism was not observed in our study. Also the occurrence of overt hyperthyroidism was too low in our study (0.01%) to be able to evaluate the factors responsible for their occurrence. In our study, IRIS was not a predictor of thyroid dysfunction.
In our study, none of the antiretroviral agents were predictors of occurrence of subclinical hypothyroidism. Studies evaluating the link between HAART and thyroid dysfunction have given conflicting results, with some but not all studies observing a link [6, 7] . A large cross-sectional study in 350 patients did not observe any link between HAART and occurrence of subclinical hypothyroidism [6] . Afhami et al. documented similar observations in a cross-sectional study of 85 HIV infected patients [31] . A higher than expected incidence of hypothyroidism (10.7 per 1000 treated patient years) but not hyperthyroidism (3.7 per 1000 treated patient years)
